# US 2006/0154943 A1 · Benzofuran derivatives and their use in the treatment of microbial infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154943 A1
- Document ID: US20060154943A1
- Status: Published application
- Kind: A1
- Application number: 10/563,938
- Filed: 2004-07-08
- Published: 2006-07-13
- Earliest claimed: 2003-07-11
- Assignees: Arpida AG
- Inventors: Sorana Greiveldinger-Poenaru; Dieter Gillessen; Kaspar Burri
- Web page: https://patentgrep.com/patent/US20060154943A1

## CPC

- C07D 405/14: containing three or more hetero rings
- A61P 31/04: Antibacterial agents
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to new benzofuran derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as anti-infectives.

## Claims

### Claim 1

A compound of formula I
wherein
R1 represents the groups
whereby in these groups R5 is hydrogen, lower alkyl with 1 to 4 carbon atoms, or the group
wherein
R8 represents, lower alkyloxy, lower alkylamino, or lower alkyl with 1 to 4 carbon atoms;
R9 represents, lower alkyl with 1 to 4 carbon atoms;
R8 and R9 together form a 5- or 6-membered heterocyclic ring containing one to two hetero atoms which can be the same or different and are oxygen or nitrogen;
R6 represent hydrogen, halogen, nitro, or lower alkyloxy;
R7 represents hydrogen;
R2 and R3 independently represent hydrogen, lower alkyl with 1 to 3 carbon atoms, or together a lower alkylene group with 1 to 3 carbon atoms bridging the oxygen atoms and forming a five, six or seven membered ring;
R4 represents hydrogen
and pharmaceutically acceptable salts thereof.

### Claim 2

A compound of formula I′
wherein
R1 represents the groups
whereby in these groups R5 is hydrogen, lower alkyl with 1 to 4 carbon atoms, or the group
wherein
R8 represents, lower alkyloxy, or lower alkyl with 1 to 4 carbon atoms;
R9 represents, lower alkyl with 1 to 4 carbon atoms;
R8 and R9 together form a 5- or 6-membered heterocyclic ring containing one to two hetero atoms which can be the same or different and are oxygen or nitrogen;
R6 represent hydrogen, halogen, nitro, or lower alkyloxy;
R7 represents hydrogen;
R2 and R3 independently represent hydrogen, lower alkyl with 1 to 3 carbon atoms, or together a lower alkylene group with 1 to 3 carbon atoms bridging the oxygen atoms and forming a five, six or seven membered ring;
R4 represents hydrogen;
and pharmaceutically acceptable salts thereof.

### Claim 3

A compound of formula II
wherein
R2 and R3 represent methyl;
R4 represents hydrogen;
R5 and R6 are as defined in formula I;
R7 represents hydrogen;
and pharmaceutically acceptable salts thereof.

### Claim 4

A compound of formula III
wherein
R2 and R3 represent methyl;
R4 represents hydrogen;
R5 and R6 are as defined in formula I;
R7 represents hydrogen;
and pharmaceutically acceptable salts thereof.

### Claim 5

A compound of formula IV
wherein
R2 and R3 represent methyl;
R4 represents hydrogen;
R5 and R6 are as defined in formula I;
R7 represents hydrogen;
and pharmaceutically acceptable salts thereof.

### Claim 6 (depends on 1)

The compound of claim 1 selected from the group consisting of:
5-[6,7-Dimethoxy-2-(7-methoxy-1H-indol-3-ylmethyl)-benzofuran-4-ylmethyl]-pyrimidine-2,4-diamine;
5-[6,7-Dimethoxy-2-(5-methoxy-1H-indol-3-ylmethyl)-benzofuran-4-ylmethyl]-pyrimidine-2,4-diamine;
5-[2-(1H-Indol-3-ylmethyl)-6,7-dimethoxy-benzofuran4-ylmethyl]-pyrimidine-2,4-diamine;
5-[6,7-Dimethoxy-2-(2-methyl-1H-indol-3-ylmethyl)-benzofuran-4-ylmethyl]-pyrimidine-2,4-diamine;
5-[2-(6-Fluoro-1H-indol-3-ylmethyl)-6,7-dimethoxy-benzofuran-4-ylmethyl]-pyrimidine-2,4-diamine;
{3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indol-2-yl}-morpholin-4-yl-methanone;
3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indole-2-carboxylic acid dimethylamide;
5-[6,7-Dimethoxy-2-(5-nitro-1H-indol-3-ylmethyl)-benzofuran-4-ylmethyl]-pyrimidine-2,4-diamine;
{3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indol-2-yl}-pyrrolidin-1-yl-methanone;
3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-5-methoxy-1H-indole-2-carboxylic acid dimethylamide;
3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indole-2-carboxylic acid methoxy-methyl-amide;
5-Chloro-3-[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indole-2-carboxylic acid dimethylamide;
3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-5-fluoro-1H-indole-2-carboxylic acid dimethylamide;
5-Chloro-3-[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indole-2-carboxylic acid methoxy-methyl-amide;
3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-1H-indole-2-carboxylic acid N,N′-dimethyl-hydrazide;
3-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-5-fluoro-1H-indole-2-carboxylic acid methoxy-methyl-amide;
and pharmaceutically acceptable salts thereof.

### Claim 7 (depends on 1, 2)

An intermediate compound of formula XI and XII
wherein R2, R3, R4, R5 and R6 have the meaning given in formula I in claim 1 and 2.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising one or more compounds of claim 1 and a pharmaceutically acceptable inert carrier material.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 1)

A process for the manufacture of a pharmaceutical composition containing one or more compounds as claimed in claim 1 as active ingredients, which process comprises mixing one or more active ingredients with a pharmaceutically acceptable inert carrier material and/or an adjuvant.

### Claim 17

(canceled)

### Claim 18 (depends on 6)

A process for the manufacture of a pharmaceutical composition comprising one or more compounds as claimed in claim 6 as active ingredients, which process comprises mixing one or more active ingredients with a pharmaceutically acceptable inert carrier material and/or an adjuvant.

### Claim 19 (depends on 6)

A pharmaceutical composition comprising one or more compounds of claim 6 and a pharmaceutically acceptable inert carrier material.

### Claim 20 (depends on 1)

A method for treating a bacterial infection comprising administering to a subject in need thereof an effective amount of the compound of claim 1.

### Claim 21 (depends on 20)

The method of claim 20, wherein the bacterial infection is caused by a Gram positive pathogen or Gram negative pathogen.

### Claim 22 (depends on 6)

A method for treating a bacterial infection comprising administering to a subject in need thereof an effective mount of the compound of claim 6.

### Claim 23 (depends on 22)

The method of claim 22, wherein the bacterial infection is caused by a Gram positive pathogen or Gram negative pathogen.
